Virtual Library
Start Your Search
Edurne Arriola Aperribay
Author of
-
+
Challenges in clinical oncology: YO case discussions (ID 14)
- Event: ELCC 2019
- Type: Educational session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 4/11/2019, 09:00 - 10:30, Room C
-
+
Mentor guided discussion (ID 615)
09:00 - 10:30 | Presenting Author(s): Edurne Arriola Aperribay
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Lunch & Poster Display session (ID 58)
- Event: ELCC 2019
- Type: Poster Display session
- Track:
- Presentations: 2
- Moderators:
- Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
-
+
141P - Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p) (ID 565)
12:30 - 13:00 | Author(s): Edurne Arriola Aperribay
- Abstract
Background
CNS is a common site of metastases in patients with ALK-positive NSCLC. CNS metastases are associated with a number of deleterious effects, such as reduction in quality of life. However, the relationship between brain metastases and prognosis remains unclear. We aimed to evaluate the effect of CNS metastases on overall survival (OS) in a multicenter cohort of Spanish ALK-positive NSCLC patients diagnosed between 2008 and 2017.
a9ded1e5ce5d75814730bb4caaf49419 Methods
We included patients with stage IV at diagnoses, followed up to April 2018; OS (months [m]) was estimated with the Kaplan-Meier method. Survival curves were compared between groups of patients using the log-rank test. Hazard risk (HR) to death was estimated with multivariable Cox model.
20c51b5f4e9aeb5334c90ff072e6f928 Results
Out of 163 patients in the cohort, a total of 116 were evaluated, with a median of follow-up of 29.2 m and 59 deaths reported. Characteristics at diagnosis were a median age of 58 years, 50% female, 58.6% never-smokers, 54.3% with comorbidities, PS by ECOG 0-1 93.1%. CNS metastases (median number of lesions 6) were present in 43.1% of patients and 34% of patients with CNS metastases were treated with local therapy (11.8 % local radiotherapy and 76.5% holocraneal radiotherapy). ALK inhibitors as first line and second line treatment were administered to 45.5% and 78.6% of patients, respectively. The median OS was 39 months; OS in patients with CNS metastases at diagnosis was 34.4 m and 39.0 m in those without CNS metastases at diagnosis (
fd69c5cf902969e6fb71d043085ddee6 Conclusionsp =.9). In patients without CNS metastases at baseline (n=60), 22 developed CNS, with a median OS greater than in those without CNS metastases during follow-up, although the difference is not significant (45.5 m vs 33.3 m;p =.9). There were 81 patients who presented with metastases in more than one organ and 33 patients with metastases in a single organ. The risk of death increased as the number of metastatic organs at diagnoses increased (HR=1.26,p =.0305), with worse OS in those presenting with liver metastases at diagnoses (21.1%, OS: 20 m), compared to those without tumor involvement (OS: 45.4 m; p =.008).
OS was similar for ALK-positive NSCLC patients with and without CNS metastases at diagnoses. OS was worse as the number of metastatic organs at diagnosis increased, with liver metastases being associated with the highest risk of mortality.
b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
Catalan Oncology Institute.
213f68309caaa4ccc14d5f99789640ad Funding
Has not received any funding.
682889d0a1d3b50267a69346a750433d Disclosure
All authors have declared no conflicts of interest.
cffcb1a185b2d7d5c44e9dc785b6bb25 -
+
81P - Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer (ID 396)
12:30 - 13:00 | Author(s): Edurne Arriola Aperribay
- Abstract
Background
Patients with advanced NSCLC (Non-small cell lung cancer) benefit from ICIs (immune checkpoint inhibitors) as part of their treatment strategy. This benefit might also be observed in earlier stages. The aim of our work was to characterize the immune contexture of early NSCLC and assess the impact on outcome of immune biomarkers.
a9ded1e5ce5d75814730bb4caaf49419 Methods
Formalin-fixed paraffin embedded (FFPE) 1 mm cores from patients that underwent curative surgical treatment between 2006 and 2018 at Hospital del Mar (Barcelona, Spain), and did not received neoadjuvant therapy were included in a tissue microarray. PD-L1 expression as well as CD3, CD4, CD8, CD80 and CD103 were evaluated by immunohistochemistry. We report the percentage of positive cells for each marker from all nucleated cells. We evaluated the association between clinicopathological and molecular characteristics and immune biomarkers (Mann-Whitney, Kruskal-Wallis and Spearman correlation) and their impact on survival outcomes (Cox regression).
20c51b5f4e9aeb5334c90ff072e6f928 Results
Samples from 195 patients were included (Adenocarcinomas N = 130, Squamous cell carcinoma N = 61, Other histology N = 4). In our cohort, 74.9% of the cases were males, predominantly smokers (87.2%). Tumor size was less or equal than 40mm in 72.3% of the cases. Stage I, II, III and IV tumors represent 44.6%, 25.1% and 26.7% of all cases included in our study, respectively. PD-L1 expression was <1%, 1 - <50% and ³50%, in 46.7%, 29.2% and 24.1% of the cases respectively. PD-L1 expression was positively correlated with higher percentage of CD4 (rho=0.195), CD8 (rho=0.3272), CD80 (rho=0.2152) and CD103 (rho=0.4237) (all p-values<0.05). CD103 expression was positively correlated with CD80 expression (rho=0.514; p < 0.001). A higher percentage of lymphocytes measured by CD3 expression in tumor tissue was correlated with better overall survival (p = 0.045; HR = 0.98 (0.96-0.99)) when adjusted by TNM 8thedition stage and adjuvant chemotherapy. No correlations with clinicopathological features were observed.
fd69c5cf902969e6fb71d043085ddee6 Conclusions
Immune biomarker expression is highly heterogeneous in early NSCLC. Lymphocyte infiltration is associated with higher PD-L1 expression. Evaluation of immune biomarkers might better inform the choice of adjuvant treatment for NSCLC patients.
b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
The authors.
213f68309caaa4ccc14d5f99789640ad Funding
Has not received any funding.
682889d0a1d3b50267a69346a750433d Disclosure
All authors have declared no conflicts of interest.
cffcb1a185b2d7d5c44e9dc785b6bb25
-
+
Optimal management of brain metastases in NSCLC (ID 47)
- Event: ELCC 2019
- Type: Educational session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 4/13/2019, 09:40 - 11:10, Room C
-
+
Sequencing systemic therapy with driver mutations (ID 120)
09:40 - 11:10 | Presenting Author(s): Edurne Arriola Aperribay
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
